Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.
Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab (Darzalex) to the triplet regimen bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Dara-RVd) in patients with multiple myeloma.
In previous trials, RVd induction therapy performed well for both patients with transplant eligible disease as well as transplant ineligible, Voorhees says. In addition, the IFM 2009 trial showed that lenalidomide induction followed by transplant with lenalidomide consolidation and 1 year of lenalidomide maintenance demonstrated a complete response rate of 60% and median progression-free survival of 50 months.
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More